Oral News and Research

RSS

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Pierre Fabre Dermatologie has obtained marketing authorization from the FDA for the pediatric drug Hemangeol (propranolol hydrochloride), which is the first and only approved treatment for "proliferating infantile hemangioma requiring systemic therapy".

18 Mar 2014

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use.

16 Mar 2014

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb Company and Pfizer Inc. today announced that the U.S. Food and Drug Administration approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

16 Mar 2014

Study shows effect of oral fungal yeast in inhibiting thrush

Scientists at Case Western Reserve School of Medicine and University Hospitals (UH) Case Medical Center have discovered how the beneficial fungal yeast, Pichia, holds at bay a harmful fungal yeast, Candida.

14 Mar 2014

TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

TaiGen Biotechnology Company, Limited today announced that the Taiwan Food and Drug Administration has approved the new drug application (NDA) of Taigexyn (nemonoxacin) oral formulation (500 mg) for the treatment of community-acquired bacterial pneumonia (CAP). With this NDA approval, Taiwan is the first region to grant marketing approval to Taigexyn.

13 Mar 2014

SAGE Therapeutics announces completion of $38 million Series C financing

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat specialty, critical and orphan central nervous system (CNS) disorders, today announced the successful completion of a $38 million Series C financing. OrbiMed Advisors, LLC, EcoR1 Capital Management, Foresite Capital Management and two undisclosed blue chip public investment funds joined existing investors Third Rock Ventures and ARCH Venture Partners.

13 Mar 2014

N30 Pharma begins oral dosing in N91115 Phase 1 trial for treatment of cystic fibrosis

N30 Pharmaceuticals, Inc. announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF).

12 Mar 2014

Rexahn reports initial results from Supinoxin Phase I trial in patients with solid cancer tumors

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.

11 Mar 2014

NeuroDerm enrolls patients in second ND0612 Phase II clinical trial for treatment of Parkinson's disease

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease.

11 Mar 2014

Some "junk foods" can help child's oral health

If there's one thing that all dentists have in common, it's that they regularly see young patients with tooth decay. Roughly 41 percent of children age 2-11 have had decay in their primary teeth, while approximately 32 percent of children ages 9-11 have decay in their permanent teeth.

11 Mar 2014

Glucosamine not reduces knee cartilage deterioration among individuals with chronic knee pain

A short-term study found that oral glucosamine supplementation is not associated with a lessening of knee cartilage deterioration among individuals with chronic knee pain.

11 Mar 2014

Sleep apnoea may be risk factor for pneumonia

People who suffer from sleep apnoea face an increased risk of developing pneumonia, a large epidemiological study indicates.

10 Mar 2014

FDA accepts Lundbeck's carbamazepine NDA for review

Lundbeck LLC today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug (AED) carbamazepine. An action letter is anticipated before the end of 2014. Carbella is the proposed U.S. trade name for intravenous carbamazepine.

10 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

Trophos' olesoxime shows beneficial effect on maintaining motor function in SMA patients

Trophos today announces that top-line results from a pivotal clinical trial of its lead product candidate olesoxime in spinal muscular atrophy (SMA) show a beneficial effect on the maintenance of motor function in SMA patients. If approved, olesoxime could be the first treatment specifically developed for SMA patients.

10 Mar 2014

Tubulin protein is a well-validated cancer drug target

Tubulin, the building-block protein of cellular microtubules, is a well-validated cancer drug target: Disrupting tubulin polymerization affects cytoskeletal function and thus cell division.

10 Mar 2014

Biodegradable scaffolds promote tissue growth during the healing process

Researchers from the University of Pittsburgh's Swanson School of Engineering and McGowan Institute for Regenerative Medicine (MIRM) are proposing that if 3-D printers, or additive manufacturing, can produce custom replacement parts for machines, why couldn't the same process create biodegradable tissue repair structures for the human body?

7 Mar 2014

Oral News and Research

Pierre Fabre Dermatologie receives FDA marketing authorization for pediatric drug Hemangeol

Merck's NOXAFIL injection gets FDA approval for intravenous use

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Study shows effect of oral fungal yeast in inhibiting thrush

TFDA approves TaiGen's Taigexyn NDA for treatment of community-acquired bacterial pneumonia

SAGE Therapeutics announces completion of $38 million Series C financing

N30 Pharma begins oral dosing in N91115 Phase 1 trial for treatment of cystic fibrosis

Rexahn reports initial results from Supinoxin Phase I trial in patients with solid cancer tumors

NeuroDerm enrolls patients in second ND0612 Phase II clinical trial for treatment of Parkinson's disease

Some "junk foods" can help child's oral health

Glucosamine not reduces knee cartilage deterioration among individuals with chronic knee pain

Sleep apnoea may be risk factor for pneumonia

FDA accepts Lundbeck's carbamazepine NDA for review

Antares Pharma announces launch of OTREXUP to Dermatologists

Trophos' olesoxime shows beneficial effect on maintaining motor function in SMA patients

Tubulin protein is a well-validated cancer drug target

Biodegradable scaffolds promote tissue growth during the healing process

Epigenetics has much to offer in future treatment and prevention of dental disease, says dentist

Alkermes initiates pivotal clinical development program for treatment of MDD

Tetraphase Pharmaceuticals reports net loss of $11.3 million for Q4 2013

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News